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ABSTRACT
The most well-known mechanism of metformin action, one of the most commonly pre-
scribed antidiabetic drugs, is adenosine monophosphate-activated protein kinase activa-
tion; however, recent investigations have shown that adenosine monophosphate-activated
protein kinase-independent pathways can explain some of metformin’s beneficial meta-
bolic effects as well as undesirable side-effects. Such novel pathways include induction of
mitochondrial stress, inhibition of mitochondrial shuttles, alteration of intestinal microbiota,
suppression of glucagon signaling, activation of autophagy, attenuation of inflammasome
activation, induction of incretin receptors and reduction of terminal endoplasmic reticulum
stress. Together, these studies have broadened our understanding of the mechanisms of
antidiabetic agents as well as the pathogenic mechanism of diabetes itself. The results of
such investigations might help to identify new target molecules and pathways for treat-
ment of diabetes and metabolic syndrome, and could also have broad implications in dis-
eases other than diabetes. Accordingly, new antidiabetic drugs with better efficacy and
fewer adverse effects will likely result from these studies.
INTRODUCTION
Metformin (1, 1-dimethylbiguanide hydrochloride) has been
widely used to treat type 2 diabetes since the 1950s1, and is
currently the drug of choice recommended by the American
Diabetes Association and the European Association for the
Study of Diabetes2. Although the detailed mechanisms underly-
ing the metabolic effects of metformin have not been com-
pletely elucidated, the most commonly accepted mechanism is
activation of adenosine monophosphate (AMP)-activated pro-
tein kinase (AMPK; Figure 1)3,4. AMPK is a highly conserved
serine/threonine protein kinase composed of a catalytic a sub-
unit and two regulatory b and c subunits, and is activated by
an increased AMP : adenosine triphosphate (ATP) ratio in
metabolic stress conditions, such as hypoxia or glucose depriva-
tion5. Thus, AMPK can act as a sensor of cellular energy levels.
However, recent studies have also suggested AMPK-indepen-
dent pathways as important mechanisms of action of metfor-
min6. For example, it has been reported that metformin-
induced suppression of glucose production is more pronounced
in AMPKa1a2-null hepatocytes compared with control cells7.
In the present review, we summarize recent ﬁndings on the
new mechanisms of metformin, focusing especially on AMPK-
independent mechanisms, such as alterations of mitochondria
and the gut. We also discuss the recent ‘hot’ issue of intestinal
microbiota as it relates to metformin activity.
MITOCHONDRIAL STRESS AND METFORMIN
Metformin and phenformin, another biguanide drug, both have
been reported to inhibit the activity of mitochondrial com-
plex I8. The inhibition of mitochondrial complex activity by
metformin might be a mechanism of metformin-induced
AMPK activation9, as intracellular ATP levels are decreased by
the inhibition of mitochondrial complex activity and AMP lev-
els are increased by the action of adenylate kinase converting
two molecules of adenosine diphosphate (ADP) to ATP and
AMP (Figure 1). AMP molecules can then bind to the c sub-
unit of AMPK and activate AMPK activity directly or by inhib-
iting dephosphorylation of AMPK phosphorylated by liver
kinase B1 (LKB1) or calcium/calmodulin-dependent protein
kinase kinase-b (CAMKKb)10.
Mitochondrial stress can affect tissue metabolism indepen-
dent of AMPK. Speciﬁcally, mitochondrial stress has been
shown to initiate an integrated stress response (ISR)11 through
activating transcription factor 4 (ATF4) to induce ﬁbroblastReceived 20 December 2014; revised 26 December 2014; accepted 5 January 2015
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growth factor 21 (FGF21), which in turn improves the meta-
bolic proﬁle associated with obesity or lipid injury as a ‘mitoki-
ne’12. A recent investigation examined whether metformin
could induce a similar ISR by inducing mitochondrial stress.
As hypothesized, metformin was able to induce the expression
of FGF21 through the double-stranded ribonucleic acid-acti-
vated protein kinase-like endoplasmic reticulum (ER) kinase
(PERK)-eukaryotic initiation factor 2a–ATF4 axis in hepato-
cytes, which was attributed to the inhibition of mitochondrial
complex I activity (Figure 1)13. Metformin-induced FGF21
expression was still observed in AMPKa1-dominant negative
transfectants or AMPKa1a2-null mouse embryonic ﬁbroblast
cells, suggesting an AMPK-independent ISR leading to FGF21
induction. Treatment with (2-(2,2,6,6-tetramethylpiperidin-1-
oxyl-4-ylamino)-2-oxoethyl) triphenylphosphonium chloride
monohydrate (MitoTempo), a mitochondrial reactive oxygen
species (ROS)-speciﬁc quencher not only reversed mitochon-
drial ROS production by metformin, but also attenuated
FGF21 induction after metformin treatment, supporting the
role of mitochondrial stress or mitochondrial ROS in the
induction of FGF21. Serum levels of FGF21 were increased by
in vivo administration of metformin in mice, suggesting the
contribution of FGF2 in the metabolic effect of metformin
administration in vivo. Finally, serum FGF21 levels were
increased in patients with type 2 diabetes after metformin ther-
apy for 6 months, supporting the possible role of FGF21 induc-
tion in metabolic improvement by metformin administration to
human patients with diabetes13.
Mitochondrial stress induced by metformin or other mea-
sures might have broad implications in addition to FGF21
induction. Indeed, several recent investigations have examined
the relationship between mitochondrial stress response, metabo-
lism and longevity in the Caenorhabditis elegans model14,15.
Speciﬁcally, these studies showed that imbalances between
mitochondrial and nuclear protein synthesis by genetic manip-
ulation, nicotinamide adenine dinucleotide (NAD+) supplemen-
tation or sir-2.1 expression activates the mitochondrial
unfolded protein response and increases longevity. Such a rela-
tionship between mitochondrial stress and longevity might
also be involved in the increased life span of experimental mice
Figure 1 | Metformin inhibits mitochondrial complex I, mitochondrial shuttle and glucagon signaling. Metformin diminishes mitochondrial
complex I activity. Decreased adenosine triphosphate (ATP) and increased adenosine monophosphate (AMP) content by metformin as a result of
decreased mitochondrial complex activity contributes to adenosine monophosphate-activated protein kinase (AMPK) activation. Mitochondrial
reactive oxygen species (ROS) production as a result of mitochondrial complex I inhibition leads to integrated stress response (ISR) through
activation of double-stranded ribonucleic acid-activated protein kinase-like endoplasmic reticulum (ER) kinase at the mitochondria-associated
membrane site between mitochondria and ER94, followed by eukaryotic translation factor 2a (eIF2a) phosphorylation and activating transcription
factor 4 (ATF4) induction. ATF4 induces fibroblast growth factor 21 (FGF21). Metformin inhibits mitochondrial glycerophosphate dehydrogenase
(mGPD), but not cytosolic glycerophosphate dehydrogenase (cGPD). Inhibition of mGPD impedes conversion of glycerol-3-phosphate (G3P) to
dihydroxyacetone phosphate (DHAP), and blocks gluconeogenesis from glycerol that needs to be converted to G3P and then to DHAP for
gluconeogenesis. Decreased cytosolic oxidized form of nicotinamide adenine dinucleotide (NAD+) leads to the accumulation of lactate, which is
frequently observed during metformin treatment. Increased AMP after metformin treatment inhibits adenylate cyclase and reduces 30-50-cyclic
adenosine monophosphate (cAMP) content, which attenuates glucagon-induced gluconeogenic gene expression mediated by protein kinase A
(PKA).
ª 2015 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd J Diabetes Investig Vol. 6 No. 6 November 2015 601
R E V I EW A R T I C L E
http://onlinelibrary.wiley.com/journal/jdi New mechanisms of metformin action
following metformin administration16, although it is still
unclear whether the relationship between mitochondrial stress
and longevity observed in C. elegans also extends to the verte-
bral system17.
MITOCHONDRIAL SHUTTLE AND METFORMIN
One of the main metabolic features of metformin is its ability
to reduce hepatic glucose production18. A recent study sug-
gested that inhibition of mitochondrial glycerophosphate dehy-
drogenase (mGPD), a critical enzyme in the glycerophosphate
shuttle, could be the primary mechanism of metformin-
induced inhibition of gluconeogenesis (Figure 1)19. Speciﬁcally,
the glycerophosphate shuttle together with the malate-aspartate
shuttle allows a cytoplasmic reduced form of nicotinamide
adenine dinucleotide (NADH) generated by glycolysis to enter
mitochondria for production of ATP and regeneration of cyto-
plasmic NAD+. The inhibition of the mitochondrial shuttle
leads to the increased cytosolic redox state and decreased
mitochondrial redox state. Thus, an increased cytosolic redox
state could impair conversion of lactate to pyruvate by lactate
dehydrogenase, leading to decreased gluconeogenesis and accu-
mulation of lactate. The latter effect is frequently observed in
animals and humans treated with metformin, and could be
the cause of lactic acidosis, a well-known side-effect of metfor-
min. Gluconeogenesis from glycerol can also be impaired, as
conversion from glycerol-3-phosphate to dihydroxyacetone
phosphate by mGPD in the mitochondrial matrix, a necessary
step for gluconeogenesis from glycerol, is inhibited by metfor-
min (Figure 1)19. This ﬁnding could represent a novel mecha-
nism of metformin that can explain its ability to inhibit
gluconeogenesis and lactate overproduction, although it is not
clear whether the inhibition of the glycerophosphate shuttle,
which represents only a small portion of ATP production, can
lead to signiﬁcant changes in the cellular redox state20. These
results might also potentially contribute to the identiﬁcation of
new molecular targets for development of a novel class of
antidiabetic agents.
GLUCAGON AND METFORMIN
Another novel mechanism explaining decreased gluconeogene-
sis by metformin was recently proposed. Metformin was shown
to inhibit glucagon signal transduction by decreasing 30-50-cyclic
adenosine monophosphate (cAMP) production in hepato-
cytes21. Decreased cAMP content leads to decreased activity of
both cAMP-dependent protein kinase A, an important signal
transducer of glucagon action and glucagon-induced gluconeo-
genesis (Figure 1). Decreased cAMP was attributed to the direct
inhibition of adenylate cyclase by increased intracellular AMP
content after metformin treatment rather than AMPK activa-
tion. Increased AMP content could be a result of the aforemen-
tioned inhibition of mitochondrial complex I activity
and reduced hepatic energy charge by metformin treatment
(Figure 1). Together, these results suggest a novel mechanism
of metformin action related to glucagon signaling, and a
potential role of adenylate cyclase as a new therapeutic target
for the treatment of type 2 diabetes.
INTESTINAL MICROBIOTA AND METFORMIN
Accumulating data suggest that gut microbiota play an impor-
tant role in the control of energy balance by extracting energy
from ingested food22. Intestinal microbiota also play a crucial
role in the maturation of gut immunity and maintenance of
immune homeostasis23. The human gut microbiota comprises
10–100 trillion microorganisms of more than 1,000 species24,25.
Furthermore, recent studies have shown that changes in gut
microbiota could be important in the pathogenesis of the obese
and diabetic phenotypes. For example, germ-free mice are pro-
tected against diet-induced obesity, which is accompanied by
increased levels of AMPK activity in the liver or muscle tissue
and derepression of fasting-induced adipose factor (Fiaf)22,26.
As Fiaf is an inhibitor of lipoprotein lipase, Fiaf could inhibit
the storage of lipid in adipose tissue in germ-free mice. In addi-
tion, obesity and high-fat diets are associated with a signiﬁcant
increase in the relative abundance of the Firmicutes phylum
and decrease in the Bacteroidetes phylum27,28. Furthermore,
transplantation of gut microbiota from obese mice to germ-free
mice leads to a signiﬁcant increase in body fat content and
insulin resistance compared with those from lean mice29.
Previous studies have shown that the intestines play a signiﬁ-
cant role in the glucose-lowering effect of metformin by facili-
tating uptake and utilization of glucose30,31 (Figure 2). The
concentration of metformin reaches a higher level in the intesti-
nal mucosa compared with other tissues30,31, which might be
related to the adverse effects of metformin on the gastrointesti-
nal tract. Based on the signiﬁcant potential impact of metfor-
min on the intestine, whether metformin affects the gut
microbiota was investigated, and also if the metabolic effects of
metformin are related to changes in the gut microbiota. When
microbiota abundance was studied using 16S ribosomal ribonu-
cleic acid pyrosequencing, marked changes in microbiota com-
position by metformin treatment were observed, particularly in
high-fat diet (HFD)-fed conditions, suggesting a possible inter-
action between HFD, metformin and intestinal microbiota.
Nearest shrunken centroid analysis showed signiﬁcant changes
of 29 genera of six phyla, with Akkermansia belonging to the
Verrucomicrobia phylum representing one of the genera show-
ing the most conspicuous changes32. Akkermansia muciniphila
is a recently identiﬁed Gram-negative anaerobic bacteria that
can enhance mucin production by degrading mucin33. When
cultured Akkermansia was administered instead of metformin,
the metabolic proﬁle of HFD-fed mice was improved, similar
to the metabolic changes induced by metformin. The numbers
of mucin-producing goblet cells were also increased similarly
by metformin or Akkermansia administration (Figure 2). These
data are supported by another study showing that metformin
treatment induces intestinal mucin 2 and mucin 5 expression,
and that Akkermansia is enriched by metformin in an in vitro
culture system34. Improvement of the metabolic proﬁle by met-
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formin or Akkermansia administration was also associated with
the reversal of diminished regulatory T cell number and down-
regulation of elevated interleukin (IL)-1b and IL-6 messenger
ribonucleic acid expression in visceral adipose tissue of mice
fed a HFD (Figure 2). These results suggest that metformin or
Akkermansia improves the metabolic proﬁle of diet-induced
obesity by ameliorating low-grade tissue inﬂammation, a cause
of insulin resistance associated with obesity.
Consistent with the studies aforementioned, Akkermansia has
been shown to upregulate the intestinal expression of several
endocannabinoids controlling inﬂammation, barrier function
and peptide secretion in the gut35, which in turn lead to
improvement of diet-induced metabolic deterioration36. Metfor-
min has also been reported to restore impaired gut barrier
function in animals with fructose-induced liver steatosis, sup-
porting the beneﬁcial effects of metformin or Akkermansia in
the intestine37. The role of Akkermansia as an agent contribut-
ing to the improvement of the metabolic proﬁle was substanti-
ated by several other studies that showed increased abundance
of Akkermansia after gastric bypass surgery38, and in a ‘high
gene count’ group characterized by lower adiposity and less
insulin resistance among the general population39. In contrast,
a metagenome-wide association study reported enrichment of
Akkermansia in samples from patients with type 2 diabetes40. It
is possible that such differences could be a result of patient
selection, because composition of the gut microbiota can
change during the course of treatment with antidiabetic agents,
such as metformin. The molecular mechanism of the restora-
tion of regulatory T cells and downregulation of tissue inﬂam-
mation by metformin or Akkermansia remains unclear.
However, a recently reported role of mucin in the tolerization
of intestinal dendritic cells and inhibition of nuclear factor
kappa-light-chain-enhancer of activated B cells signaling might
contribute to this process41.
The effect of metformin on gut microbiota has also been
studied using non-vertebrate in vivo models. Intriguingly, met-
formin was reported to increase the healthspan and lifespan of
both mice and C. elegans16,42. A recent paper provided evidence
that retardation of aging of C. elegans by metformin is a result
of the altered folate and methionine metabolism of intestinal
microbiota of C. elegans, leading to reduced methionine
availability and calorie restriction-like effects in the host
(Figure 2)43. These results suggest that metformin inﬂuences
the microbiota of both nematodes and mammals, which might
be involved in metabolic improvement and possibly lifespan
extension44.
INCRETIN AND METFORMIN
Incretins are a group of gastrointestinal hormones that increase
insulin release after food ingestion, and comprise glucagon-like
Figure 2 | Effects of metformin on the gut. Metformin induces glucagon-like peptide 1 (GLP-1) release from intestinal L cells, and also GLP-1
receptor expression on pancreatic b-cells. Metformin increases the abundance of Akkermansia, a mucus-degrading Gram-negative bacteria, in the
gut, which is associated with restoration of reduced regulatory T (Treg) cells and amelioration of low-grade tissue inflammation in the adipose
tissue of obese animals. Increased life span of Caenorhabditis elegans by metformin has also been attributed to changes in intestinal microbiota.
The intestine is a major organ responsible for uptake and utilization of glucose after metformin administration.
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peptide 1 (GLP-1) and gastric inhibitory peptide. Incretin-based
therapies have recently been introduced in clinical practice,
where they are used to achieve improved glycemic control
without weight gain. Additionally, those therapies have potential
long-term beneﬁcial effects on islet b-cell mass and func-
tion45,46. In particular, incretin + metformin combination has
become a popular treatment. In this regard, a study exploring
the relationship between the action mechanisms of metformin
and incretin was undertaken47, which was based on the previ-
ous observation of increased plasma GLP-1 levels in obese indi-
viduals and diabetic patients treated with metformin48,49. That
study conﬁrmed that metformin administration increases
plasma levels of GLP-1, but not that of gastric inhibitory pep-
tide or peptide YY, which co-localizes with GLP-1 in intestinal
L cells (Figure 2). Increased GLP-1 levels after metformin treat-
ment were not related to the inhibition of dipeptidyl peptidase-
4 that degrades incretins or induction of proglucagon gene
expression. Furthermore, metformin might not be a direct
secretagogue of GLP-1 from intestinal L cells50. With respect to
the mechanism of the increase of plasma GLP-1 level in
response to metformin, a role of muscarinic acetylcholine
receptor has been suggested50. In that study, pretreatment with
a speciﬁc antagonist of the muscarinic M3 receptor signiﬁcantly
reduced the increase in GLP-1 levels after administration of
metformin, whereas other muscarinic receptor antagonists or
vagotomy were ineffective, suggesting the involvement of
a non-vagal M3 muscarinic pathway in metformin-induced
GLP-1 elevation50. In contrast to these results, a direct effect of
metformin in GLP-1 expression on an L cell line through Wnt
signaling has been reported51.
Intriguingly, metformin has been reported to increase
GLP-1 receptor expression on islet cells, which was dependent
on peroxisome proliferator-activated receptors pathway, but
not on AMPK activation47 (Figure 2). These results provide a
theoretical basis for combination therapies using metformin
and incretins (or dipeptidyl peptidase-4 inhibitors that increase
incretin levels), as induction of GLP-1 receptor expression by
metformin can have synergistic effects with administered incre-
tins.
AUTOPHAGY AND METFORMIN
Although metformin has AMPK-independent mechanisms for
the improvement of the metabolic proﬁle6, most investigators
agree that metformin activates AMPK4. Then, metformin can
enhance autophagy, as AMPK activation is known to upregu-
late autophagic activity through direct phosphorylation of unc-
51-like kinase and Beclin 1, key molecules involved in the initi-
ation of autophagy (Figure 3)52–54. Autophagy is a process of
subcellular membrane rearrangement to form a double-mem-
braned autophagosome enclosing cytoplasmic constituents and
organelles, which is expedited by nutrient deﬁciency55. Thus,
autophagy is important for nutrient supply in the case of
energy deﬁciency, and is also critical for the proper turnover
and function of organelles, such as mitochondria and the ER.
Figure 3 | Effects of metformin on autophagy, inflammasomes and endoplasmic reticulum (ER) stress. Metformin activates autophagy through
adenosine monophosphate-activated protein kinase (AMPK) activation and subsequent phosphorylation of unc-51-like kinase 1 (ULK1) and Beclin 1.
Autophagy expedites clearance of lipid droplets by increasing lipophagy. AMPK activation can attenuate inflammasome activation, which might
involve rejuvenation of ‘stressed’ mitochondria through mitophagy, as dysfunctional mitochondria accelerate inflammasome activation83. Lipids can
act as ligands to activate inflammasomes75. Thus, autophagy activation downregulates inflammasome activation through effects on both lipid
content and mitochondria61. AMPK attenuates thioredoxin-interacting protein (TXNIP) induction through inhibition of the recruitment of Mondo:
Max-like protein X (MLX) complexes and carbohydrate response element-binding protein (ChREBP) to the TXNIP promoter. TXNIP binds nucleotide-
binding oligomerization domain–leucine-rich repeats containing pyrin domain 3 (NLRP3) and contributes to inflammasome activation78. TXNIP
expression is increased by ER stress, which plays a role in b-cell injury through inflammasome activation86. ASC, apoptosis-associated speck-like
protein containing a caspase recruitment domain; IL, interleukin.
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As mitochondria and the ER play critical roles in pancreatic
b-cell physiology and insulin sensitivity56,57, autophagy has a
signiﬁcant impact on body metabolism. Although the effects of
autophagy deﬁciency on the body metabolism are distinct,
depending on the location and severity of autophagy deﬁ-
ciency58, a global increase in autophagic activity is likely to
improve the metabolic proﬁle under metabolic stress condi-
tions59–62, which might be related to attenuation of low-grade
tissue inﬂammation associated with obesity by autophagy acti-
vation61, as explained in the next section.
As aforementioned, autophagy induction by AMPK activa-
tion is in line with the concept that autophagy is an adaptive
process occurring in response to nutrient deﬁciency, and that
AMPK is a sensor of intracellular energy balance. In this way,
the activation of AMPK by metformin suggests the possibility
that improvement in metabolic proﬁles by metformin might
be related to autophagy induction through AMPK activation
(Figure 3). Consistent with this possibility, protection of pancre-
atic b-cells against lipoapoptosis by metformin has been attrib-
uted to activation of autophagy63,64. In addition, metformin has
been shown to enhance disposal of accumulated autophagic
vacuoles in b-cells65. Likewise, metformin has been reported to
enhance autophagic activity in cardiac tissue by facilitating dis-
sociation of the B-cell lymphoma 2 (Bcl-2)-Beclin 1 complex
through AMPK activation66 and ameliorating ultrastructural
abnormalities associated with diabetes in an animal model of
diabetic cardiomyopathy67.
In contrast to these reports showing AMPK-dependent
autophagy activation by metformin, a recent paper reported
amelioration of hepatic steatosis by metformin through auto-
phagy activation via sirtuin 1 pathway rather than AMPK
pathway68.
The target organelles of autophagy include not only the
mitochondria and ER, but also peroxisomes and lysosomes.
Additionally, lipid droplets can be the target of autophagy in a
process called lipophagy69. Thus, accelerated disposal of lipids
by lipophagy could be another mechanism of autophagy-medi-
ated amelioration of obesity-induced metabolic derangements
and tissue inﬂammation associated with obesity61 (Figure 3).
Indeed, a recent paper reported that metformin can expedite
lipophagy through forkhead box O1-mediated induction of
lysosomal acid lipase (Figure 3)70.
INFLAMMASOMES AND METFORMIN
Although type 2 diabetes has been categorized as a metabolic
disorder, the etiological role of low-grade tissue inﬂammation
in insulin resistance and b-cell dysfunction is widely
accepted71–73. Among diverse innate immune receptors, nucleo-
tide-binding oligomerization domain–leucine-rich repeats con-
taining pyrin domain 3 (NLRP3), a member of NLRP
subfamily of the Nod-like receptor (NLR) family, plays a crucial
role in the tissue inﬂammation associated with lipid overload
or obesity74,75. NLRP is critically involved in the activation of
the inﬂammasome complex, which is an essential component
in the maturation of pro-IL-1b to IL-1b76. Potential effector
molecules that can activate NLRP3 in metabolic disorders
include high glucose, lipids such as free fatty acids, and human
islet amyloid polypeptide75,77,78.
A recent paper reported that metformin inhibits IL-1b pro-
duction from macrophages of diabetic patients through AMPK
activation in vitro79. Administration of metformin to diabetic
patients for 2 months also increased AMPK activity and
decreased IL-1b maturation in macrophages of diabetic
patients. Although the molecular mechanism of the inhibition
of inﬂammasome activation by metformin has not been eluci-
dated, a recent paper suggested a potential role of autophagy
activation through AMPK. Speciﬁcally, it was reported that
metformin can increase b-amyloid clearance and decrease
IL-1b production from microglia after treatment with extracel-
lular b-amyloid ﬁbrils by inducing autophagy (Figure 3)80.
These results are consistent with previous reports showing that
autophagy deﬁciency is a pro-inﬂammatory condition charac-
terized by increased activation of inﬂammasomes81, and that
activation of autophagy can diminish inﬂammasome activa-
tion82. The mechanism of increased susceptibility of autophagy-
deﬁcient cells to inﬂammasome activation could include dis-
turbed mitochondrial homeostasis in these cells (Figure 3), as
mitochondrial dysfunction leading to altered spatial arrange-
ment could be crucial in apposition of apoptosis-associated
speck-like protein (ASC) containing a caspase recruitment
domain on mitochondria and NLRP3 on ER, and subsequent
inﬂammasome activation81,83.
ER STRESS AND METFORMIN
In addition to mitochondrial stress, ER stress might be affected
by metformin. ER stress is important in the development of
both insulin resistance and b-cell failure in diabetes57,84,85. The
mechanism of b-cell failure as a result of ER stress is not com-
pletely understood; however, several recent papers have shown
that thioredoxin-interacting protein (TXNIP) induced by irre-
mediable ER stress and inositol-requiring enzyme 1a hyperacti-
vation are critical mediators of b-cell death through activation
of inﬂammasomes86,87. TXNIP is an endogenous binding part-
ner and inhibitor of thioredoxin, an essential and ubiquitous
oxidoreductase. TXNIP expression has been reported to be
induced by high concentrations of glucose in pancreatic islet
cells, and acts as an upstream activator of the NLRP3 inﬂam-
masome after dissociation from thioredoxin by ROS78. As such,
NLRP3 activation could involve both insulin resistance and
b-cell failure74,75,88. Intriguingly, metformin has been shown to
reduce the expression of TXNIP, probably through AMPK acti-
vation, which could be involved in the inhibition of the recruit-
ment of transcription factors, such as carbohydrate response
element-binding protein or Mondo: Max-like protein X com-
plex to the TXNIP promoter (Figure 3)89,90. Together, these
results suggest a possible role of metformin in the protection of
b-cells from terminal ER stress, although such a possibility has
not yet been fully studied.
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CONCLUSIONS
Although metformin is not a new drug in the ﬁeld of antid-
iabetic medicine, new mechanisms of action continue to be
identiﬁed. Furthermore, metformin is attracting the interest
of investigators in ﬁelds other than diabetes, as metformin
has been shown to have anticancer91, immunoregulatory92
and anti-aging effects16, all of which are beyond the scope of
the present review. A review article summarizing the thera-
peutic value of metformin in diseases other than diabetes,
such as cancer or cardiovascular disorders, was recently pub-
lished93. The investigations described in the current review
and elsewhere continue to broaden our understanding of the
molecular mechanisms of metformin action and its wide
range of potential applications. Likewise, discovery of new
drugs with enhanced antidiabetic activity and reduced side-
effects with improved safety proﬁles will be aided by the
identiﬁcation of new mechanisms of action and novel targets
of metformin.
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